Vertex Pharmaceuticals Incorpor
VRTX · Healthcare
$547.65
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.
3 Stocks Whose Competitive Walls Tower Over Nvidia's
While Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex Pharmaceuticals reported Q2 2026 earnings that missed EPS estimates ($4.73 vs $4.79 consensus) but beat revenue expectations ($3.33B vs $3.23B consensus). The company raised full-year 2026 revenue guidance to $13.10-$13.20B. However, analyst estimates have trended downward over the past month despite the stock gaining 14.4%. The company received a Zacks Rank #3 (Hold) rating with a VGM Score of D, suggesting in-line returns ahead.
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics shares have gained 7.1% since its Q2 2026 earnings report, outperforming the S&P 500. The company beat earnings estimates with a narrower loss of $0.94 per share versus $1.10 expected, and revenues of $10.2 million exceeded the $7 million consensus. Vertex's Casgevy sales reached $76 million with 151% year-over-year growth. CRISPR has controlled costs across R&D, G&A, and collaboration expenses. Analysts have revised estimates upward by 10.46%, though the stock maintains a Zacks Rank #3 (Hold) with an overall VGM Score of F.